No abstract available.
Clomiphene*

No abstract available.
Clomiphene*

No abstract available.
Clomiphene*

The study included 715 anovulatory women on 1065 cycle's therapy with 3 preparations of CC: Clomid, Ovofar and Serophene. The result of ovulatory induction was approximately 50%, of clinical pregnancy was 30%. Ovofar give the clinical pregnancy a little higher (47%) of the total cycle therapy, so the loss of pregnancy (missed abortion + still abortion + GEU) is higher so (31% od the total pregnancy), in comparison with Ovofar (25%), and with Serophene (12%). The authors intend to investigate the new Clomid on the other group of women anovulatory infertility
Clomiphene ; Pregnancy ; women

It remains controversial whether the day of initiation of clomiphene citrate (cc) has any impact on endometrial quality. Objective:To determine the correlation between time of administration of clomiphene citrate and its anti-estrogenic effects on endometrial thickness and endometrial pattern. Methods: Filipino women consulting at the Philippine General Hospital for difficulty in conceiving were randomized into two groups either to start CC on cycle day two or day five. Transvaginal ultrasonography was used to determine differences in endometrial thickness and endometrial pattern between the two groups. Students t-test and chi square were used for data analysis. Results: There was no difference in endometrial thickness between the two groups. There were significantly more subjects with trilaminar endometrium in the day two groups. Conclusion: Mean endometrial thickness was similar in both arms. Earlier administration, starting day two favors the development of trilaminar endometrium.
Human ; Female ; CLOMIPHENE

BACKGROUND: Clomiphene citrate is used as the first line drug for anovulatory infertility treatment. When a woman fails to ovulate using clomiphene at maximum dose, letrozole is used as a second line drug.

OBJECTIVE: To determine association between a patient's age and body mass index (BMI) and their response to clomiphene citrate or letrozole in the treatment of anovulation-related infertility.

MATERIALS AND METHODS: The authors reviewed 147 patient records from January 2011 to August 2016 and investigated the age, BMI and response of patients when given clomiphene or letrozole for ovulation induction.

RESULTS: Ninety-nine (99) patients received clomiphene citrate while the other 118 patients received letrozole. Those who responded positively to clomiphene were at least 35 years old (72.2%) or had above normal BMI (61.5%). Patients who responded positively to letrozole were at least 35 years old (95%) and were categorized with above normal BMI (82.9%). The authors found that patients who are older than 35 years of age are more likely to respond to letrozole compared to younger patients.

CONCLUSION: This study found no significant association between BMI and response to either Letrozole or Clomiphene. Patients who are more than 35 years old are more likely to respond to letrozole, compared to younger patients. 

Heterotopic pregnancy or the coexistence of an intrauterine and an extrauterine pregnancy occurs in about 1 out of 30,000 pregnancies. Between assisted reproductive techniques and ovulation induction, it is said to occur more commonly with the former. The patient presented in this case is a 29 year old primigravid who underwent ovulation induction with clomiphene citrate and was later on diagnosed to have both an intrauterine and a non-viable extrauterine pregnancy. The management for this kind of pregnancy can be medical, surgical or expectant. The patient in this case was managed expectantly. This case study presents a review of literature on heterotopic pregnancy, and describes how this rare type of pregnancy developed in this index patient, how it is diagnosed and managed, and to showcase how expectant management can be a safe option for cases of heterotopic pregnancy.
Pregnancy, Heterotopic ; Pregnancy, Ectopic ; Clomiphene

No abstract available.
Clomiphene ; Humans ; Infertility* ; Male* ; Sinus Thrombosis, Intracranial*

OBJECTIVE: This study was to investigate the clinical efficiency of clomiphene citrate/GnRH antagonist protocol comparing with the clomiphene citrate only protocol in infertile women with normal ovulatory cycles. METHOD: Among 116 patients, 43 were received assisted reproductive technologies using natural ovulatory cycle, 38 and 35 were received clomiphene citrate only protocol and clomiphene citrate/GnRH antagonist combined protocol, respectively, and the clinical results were compared and analyzed. RESULTS: In each group, basal levels of LH, FSH, E2 and FSH, E2 on hCG day injected were not different, but LH level and endometrial thickness on hCG injected day were decreased significantly and the pregnancy rate was increased significantly in clomiphene citrate/GnRH antagonist group. CONCLUSION: The pregnancy rate was increased significantly in clomiphene citrate/GnRH antagonist group compared with natural ovulatory cycle and clomiphene citrate only group.
Clomiphene* ; Female ; Humans ; Pregnancy Rate ; Reproductive Techniques, Assisted

OBJECTIVE: This study was performed to estimate the efficacy of GnRH antagonist (cetrorelix) protocol in poor responders comparing with GnRH agonist protocol. METHODS: This study included 43 cycles of 38 patients who were defined as poor responders on previous consecutive two and more superovulation cycles. The study group consisted of 20 cycles of 18 poor responders treated with cetrorelix according to single dose protocol with clomiphene citrate, who were compared with 23 cycles of 20 poor responders (control group) stimulated according to GnRH agonist flare up protocol. RESULTS: Although the use of GnRH antagonist with clomiphene citrate gave a pregnancy rate of 15% which was in the range expected for patients with poor response, the study group had higher E2 level on hCG day (1246.5 +/- 89.4 vs 644.7 +/- 34.8 pg/ml) with higher number of mature oocytes (7.8 +/- 1.3 vs 4.3 +/- 0.5), and length of stimulation (15.5 +/- 1.4 vs 19.4 +/- 2.6 days), number of hMG ampules administered (19.4 +/- 3.2 vs 45.4 +/- 5.9 ampules), and cancellation rate (35.0 vs 47.8%) were significantly lower in the cetrorelix group. Although it was not statistically significant between two groups, the pregnancy rate (15 vs 8.6%) showed higher tendency in cetrorelix group. CONCLUSION: The use of GnRH antagonist cetrorelix ended with significantly more mature oocytes, less ampules of gonadotropin, shorter duration of stimulation and lower cancellation rate in this study. So the GnRH antagonist protocol may be an alternative protocol for the treatment of poor responders.
Clomiphene ; Gonadotropin-Releasing Hormone* ; Gonadotropins ; Humans ; Oocytes ; Pregnancy Rate ; Superovulation